3rd International Conference on
Advances and Innovative Discoveries in Chemistry

Dr. Wei Li has been working at the College of Pharmacy, the University of Tennessee Health Science Center (UTCoP) since he obtained his PhD in chemistry from Columbia University in 1999. Currently he is a Professor and the Director of the UTCoP Drug Discovery Center. His focus of research is small molecule drug discovery, and currently his research is mainly funded by NIH/NCI grants. He has published over 135 papers, 3 book chapters, five issued US patents, and additional patents from other countries. He is a frequent grant reviewer for NIH study sections, and currently he is an editorial board member for Current Medicinal Chemistry, Molecules, and Acta Pharmaceutica Sinica B

Pharmaceutical Chemistry

Cody Coyne is a professor of Molecular Pharmacology and Immunology in the Department of Basic Sciences within the College of Veterinary Medicine where he has established a research program devoted to the molecular design, synthesis and potency evaluation of pharmaceuticals. Current research investigations have been devoted to the design of molecular structure, organic chemistry reactions and multi-phase synthesis regimens for covalent immunopharmaceuticals with properties of selective "targeted" delivery and potent anti-neoplastic cytotoxicity. A native of Colorado, Coyne earned a DVM from Colorado State University in Fort Collins; completed a surgery internship, an internal medicine residency, and a PhD graduate degree (radiobiopharmacology design) at the University of California at Davis/Sacramento Medical Center, and attained board certification with diplomate status in the College of Veterinary Internal Medicine while at Kansas State University.

Current research investigations have been devoted to the design of molecular structure, organic chemistry reactions and multi-phase synthesis regimens for covalent immunopharmaceuticals with properties of selective "targeted" delivery and potent anti-neoplastic cytotoxicity.

Prof. Dr. Alireza Heidari, Ph.D., D.Sc. is a Full Professor and Academic Tenure of Chemistry at California South University (CSU), Irvine, California, USA. He has got his Ph.D. and D.Sc. degrees from California South University (CSU), Irvine, California, USA. Furthermore, he has double postdocs in Project Management, Oncology, Human Cancer Tissues and Synchrotron Radiation from Monash University, Melbourne, Victoria, Australia and also in Nanochemistry and Modern Molecular Electronic–Structure Computations Theory from California South University (CSU), Irvine, California, USA. His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc. He has participated at more than two hundreds reputed international conferences, seminars, congresses, symposiums and forums around the world as yet. Also, he possesses many published articles in Science Citation Index (SCI)/International Scientific Indexing (ISI) Journals. It should be noted that he has visited many universities or scientific and academic research institutes in different countries such as United States, United Kingdom, Canada, Australia, Scotland, Ireland, Netherlands, Belgium, Denmark, Greece, Russia, Estonia, Turkey, France, Swiss, Germany, Sweden, Italy, Austria, Hungary, Poland, South Africa, Brazil, Spain, Portugal, Mexico, Japan, Singapore, Malaysia, Thailand, Taiwan, Hong Kong, South Korea, China, India, Qatar, United Arab Emirates, etc. as research fellow, sabbatical and volunteer researcher or visitor and so on heretofore. He has a history of several years of teaching for college students and various disciplines and trends in different universities. Moreover, he has been a senior advisor in various industry and factories. He is expert in many computer programs and programming languages. Hitherto, he has authored more than twenty books and book chapters in different fields of Chemistry. Syne, he has been awarded more than eight hundreds reputed international awards, prizes, scholarships and honors. Heretofore, he has multiple editorial duties in many reputed international journals, books and publishers. Hitherward, he is a member of more than two hundreds reputed international academic–scientific–research institutes around the world. In addition, he is member of the Nobel committee for Chemistry. It should be noted that he is currently the President of American International Standards Institute (AISI), Irvine, California, USA and also Director of the BioSpectroscopy Core Research Laboratory at California South University (CSU), Irvine, California, USA

His research interests include Biophysical Chemistry, Biomolecular Spectroscopy, Quantum Chemistry, Nanochemistry, Modern Electronic Structure Computations, Theoretical Chemistry, Mathematical Chemistry, Computational Chemistry, Vibrational Spectroscopy, Molecular Modelling, Ab initio & Density Functional Methods, Molecular Structure, Biochemistry, Molecular Simulation, Pharmaceutical Chemistry, Medicinal Chemistry, Oncology, Synchrotron Radiation, LASER, Anti–Cancer Nano Drugs, Nano Drugs Delivery, ATR–FTIR Spectroscopy, Raman Spectroscopy, Intelligent Molecules, Molecular Dynamics, Biosensors, Biomarkers, Molecular Diagnostics, Numerical Chemistry, Nucleic Acids, DNA/RNA Monitoring, DNA/RNA Hypermethylation & Hypomethylation, Human Cancer Tissues, Human Cancer Cells, Tumors, Cancer Tissues, Cancer Cells, etc

Yuichi Shimazaki was born in 1970 in Toyama prefecture, Japan. He received his Doctor’s degree in science from Nagoya University in 2000 under the supervision of Professor Osamu Yamauchi. He joined Professor Yoshinori Naruta’s group at Kyushu University as Assistant Professor and worked on the redox behavior of various metal porphyrin complexes as models of the active site of metalloenzymes. In 2008 he was promoted to Associate Professor at the College of Science, Ibaraki University.

His research interests include the oxidation chemistry of the complexes of various metal ions, model studies of metalloenzymes, bioorganometallic chemistry, and weak interactions in metal-organic molecule systems.

Dr Laurent Désaubry is a CNRS research director in the University of Strasbourg in France (website: http://desaubry.u-strasbg.fr/) and adjunct professor at Tianjin University of Science and Technology (TUST) in China. In 1992, he received a Ph.D. degree in medicinal chemistry from Strasbourg University. Next, he worked as a postdoctoral fellow at SUNY at Stony Brook, USA. He made another post-doctoral internship in Prof. Pierre Chambon’s laboratory before to get a CNRS Research Senior Scientist at the University of Strasbourg-CNRS. He was promoted CNRS research director (corresponds to full professor) in 2014, and became also professor at TUST in 2015. He has published more than 70 publications and has been serving as an editorial board member of Frontiers in Chemistry, Medicinal Chemistry, Advances in Oncology Research and Treatments and The Open Medicinal Chemistry Journal.

Medicinal Chemistry

Julie received her BSc(Hons) in Chemistry from University College Cork in 2004, then began her career as a Senior QC Analyst at Pfizer. She subsequently worked for an electrochemical start-up "Anzode" in New Zealand and as an analytical chemist for Colorcon before moving into investment banking, where she used her experience managing projects to perform Execution Management at CIBC for 5 years. Julie then returned to science, obtaining an MSc in Drug Design from University College London, where she earned the Dean's Prize for her dissertation on repositioning drugs to treat malaria. She became a member of the OICR Drug Discovery team in 2017, working as a computational chemist, specifically virtual screening, providing structural insights to binding, generating homology models of proteins as well as database management for various projects. Julie has been working as a Senior Scientist on the Drug Discovery team at Cyclica since August, 2020, where she applies Cyclica's technology to drug discovery projects. Today's talk will provide an overview of Cyclica's MatchMaker technology and how Julie used Matchmaker to design a novel inhibitor for DCAF1, resulting in the first co-crystal structure of DCAF1 with a ligand to be deposited in the PDB.

Drug Discovery